AVGN Avigen (MM)

Avigen Presenting at NYSSA 7th Annual Healthcare Conference Today ALAMEDA, Calif., Nov. 18 /PRNewswire-FirstCall/ -- Avigen, Inc., , a leader in the development of gene-based drugs for serious chronic diseases, announced that its president and CEO, John Monahan, Ph.D., will make a presentation at the New York Society of Securities Analysts 7th Annual Healthcare Conference in New York City at 1:30 p.m. eastern time today, Tuesday, November 18, 2003. Dr. Monahan will provide an overview of the company's proprietary gene delivery technology and recent events in the company's primary product development programs in hemophilia and Parkinson's disease, including the filing of an IND for AV201, Avigen's ground breaking approach to the treatment of advanced Parkinson's disease. The presentation will be webcast live at http://www.shareholder.com/avigen/medialist.cfm and through Avigen's web site, http://www.avigen.com/. An archived version of the presentation will be available through December 18, 2003. About Avigen Avigen, Inc., based in the San Francisco Bay Area, focuses on the development of DNA-based drugs for serious chronic conditions. Avigen's proposed gene delivery products are designed for direct administration to patients in order to achieve expression of therapeutic proteins within the body. The company is actively enrolling subjects in its clinical trial for Coagulin-B(R), Avigen's Factor IX gene therapy product for hemophilia B, currently being conducted at the Children's Hospital of Philadelphia and Stanford University Medical Center. Patients or physicians who would like more information about enrollment criteria and the study should contact the Clinical Development Department at or call at 510-748-7379. Additional information on Avigen's proprietary gene delivery products can be found at http://www.avigen.com/ DATASOURCE: Avigen, Inc. CONTACT: Lise Needham, Associate Director of Investor Relations of Avigen, Inc., +1-510-748-7112, or Web site: http://www.shareholder.com/avigen/medialist.cfm Web site: http://www.avigen.com/

Copyright